Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 6/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 4/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4095859 | 0.84 | HSD17B1 (0.57) | HSD17B1ACHEMETAP1 | |
| SCHEMBL4086223 | 0.72 | HSD17B1 (1.00) | HSD17B1ARESR1ESR2 | |
| SCHEMBL3953461 | 0.72 | HSD17B1 (0.71) | HSD17B1ARGABRA1GABRB2ESR1 | |
| SCHEMBL13774778 | 0.71 | HSD17B1 (0.73) | HSD17B1METAP1 | |
| SCHEMBL4096696 | 0.70 | HSD17B1 (0.84) | HSD17B1 | |
| SCHEMBL13678958 | 0.70 | HSD17B1 (0.75) | HSD17B1ARGABRA1GABRB2ESR1 | |
| SCHEMBL4085986 | 0.68 | HSD17B1 (0.53) | HSD17B1ACHEMETAP1CYP19A1 | |
| SCHEMBL4093483 | 0.65 | HSD17B1 (0.50) | HSD17B1ACHEMETAP1CYP19A1 | |
| SCHEMBL16581416 | 0.65 | HSD17B1 (0.62) | HSD17B1ARGABRA1GABRB2ESR1 | |
| SCHEMBL2720462 | 0.65 | HSD17B1 (0.68) | HSD17B1ARGABRA1GABRB2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| EP-2013176-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | Sterix Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | HSD17B1 4/4885AR 104/4885GABRA1 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.